New combo targets tough pancreatic cancer in 40-patient trial
NCT ID NCT07240766
First seen Nov 21, 2025 · Last updated May 06, 2026 · Updated 20 times
Summary
This study tests a new drug combination (HRS-4642, nimotuzumab, and chemotherapy) in 40 people with a specific type of pancreatic cancer that has a KRAS G12D mutation and is borderline removable. The goal is to see if this treatment can shrink tumors enough for successful surgery and improve survival. Participants must not have had prior cancer therapy and must be between 18 and 75 years old.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Zhejiang University Schlool of Medicine
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
the First Affiliated Hospital of Zhejiang University, School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.